Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Tissue Collection and Clinical Data
2.2. Molecular Analysis
2.2.1. Fluorescence In Situ Hybridization (FISH)
2.2.2. Reverse Transcriptase–Polymerase Chain Reaction (RT-PCR)
2.2.3. Immunohistochemistry
2.3. Statistical Analysis
3. Results
3.1. Patient Demographics
3.2. Tumor Features
3.3. Treatment
3.4. Histopathological Characteristics
3.5. Survival
3.6. Progressive Unifocal Disease
3.7. Risk Stratification Model of Shibayama et al.
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lau, K.; Massad, M.; Pollak, C.; Rubin, C.; Yeh, J.; Wang, J.; Edelman, G.; Yeh, J.; Prasad, S.; Weinberg, G. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: Insights from an internet registry in the study of a rare cancer. Chest 2011, 140, 1312–1318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanas, M.R.; Sboner, A.; Oliveira, A.M.; Erickson-Johnson, M.R.; Hespelt, J.; Hanwright, P.J.; Flanagan, J.; Luo, Y.; Fenwick, K.; Natrajan, R.; et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci. Transl. Med. 2011, 3, 98ra82. [Google Scholar] [CrossRef]
- Errani, C.; Zhang, L.; Sung, Y.S.; Hajdu, M.; Singer, S.; Maki, R.G.; Healey, J.H.; Antonescu, C.R. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011, 50, 644–653. [Google Scholar] [CrossRef] [Green Version]
- Flucke, U.; Vogels, R.J.C.; de Saint Aubain Somerhausen, N.; Creytens, D.H.; Riedl, R.G.; van Gorp, J.M.; Milne, A.N.; Huysentruyt, C.J.; Verdijk, M.A.J.; van Asseldonk, M.M.; et al. Epithelioid Hemangioendothelioma: Clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases. Diagn. Pathol. 2014, 9, 131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- WHO. Classification of Soft Tissue and Bone Tumours, 5th ed.; International Agency for Research on Cancer: Lyon, France, 2020; Volume 3, pp. 172–175. [Google Scholar]
- Cournoyer, E.; Al-Ibraheemi, A.; Engel, E.; Chaudry, G.; Stapleton, S.; Adams, D.M. Clinical characterization and long-term outcomes in pediatric epithelioid hemangioendothelioma. Pediatr. Blood Cancer 2020, 67, e28045. [Google Scholar] [CrossRef]
- Orbach, D.; Van Noesel, M.M.; Brennan, B.; Corradini, N.; Alaggio, R.; Ben Arush, M.; Schoot, R.A.; Berlanga, P.; Zanetti, I.; Hjalgrim, L.L.; et al. Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience. Pediatr. Blood Cancer 2022, 69, e29882. [Google Scholar] [CrossRef]
- Rosenberg, A.; Agulnik, M. Epithelioid hemangioendothelioma: Update on diagnosis and treatment. Curr. Treat. Options Oncol. 2018, 19, 19. [Google Scholar] [CrossRef] [PubMed]
- Weiss, S.W.; Enzinger, F.M. Epithelioid hemangioendothelioma: A vascular tumor often mistaken for a carcinoma. Cancer 1982, 50, 970–981. [Google Scholar] [CrossRef]
- Deyrup, A.T.; Tighiouart, M.; Montag, A.G.; Weiss, S.W. Epithelioid hemangioendothelioma of soft tissue: A proposal for risk stratification based on 49 cases. Am. J. Surg. Pathol. 2008, 32, 924–927. [Google Scholar] [CrossRef]
- Kuo, F.; Huang, H.; Chen, C.; Eng, H.; Huang, C. TFE3-rearranged hepatic epithelioid hemangioendothelioma—A case report with immunohistochemical and molecular study. AMPIS 2017, 125, 849–853. [Google Scholar] [CrossRef]
- Sardaro, A.; Bardoscia, L.; Petruzzelli, M.F.; Portaluri, M. Epithelioid hemangioendothelioma: An overview and update on a rare vascular tumor. Oncol. Rev. 2014, 8, 259. [Google Scholar] [CrossRef] [Green Version]
- Shibuya, R.; Matsuyama, A.; Shiba, E.; Harada, H.; Yabuki, K.; Hisaoka, M. CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology 2015, 67, 827–835. [Google Scholar] [CrossRef] [PubMed]
- Antonescu, C.R.; Le Loarer, F.; Mosquera, J.M.; Sboner, A.; Zhang, L.; Chen, C.; Chen, H.; Pathan, N.; Krausz, T.; Dickson, B.C.; et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 2013, 52, 775–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Doyle, L.A.; Fletcher, C.D.; Hornick, J.L. Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics. Am. J. Surg. Pathol. 2016, 40, 94–102. [Google Scholar] [CrossRef] [PubMed]
- Jung, H.; Kim, H.N.; Jang, Y.; Park, C.K.; Ha, S.Y. CAMTA-1 Expression in 24 Cases of Hepatic Epithelioid Hemangioendothelioma in a Single Institute: Diagnostic Utility for Differential Diagnosis from Hepatic Angiosarcoma. In Vivo 2019, 33, 2293–2297. [Google Scholar] [CrossRef] [Green Version]
- Rosenbaum, E.; Jadeja, B.; Xu, B.; Zhang, L.; Agaram, N.P.; Travis, W.; Singer, S.; Tap, W.D.; Antonescu, C.R. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod. Pathol. 2020, 33, 591–602. [Google Scholar] [CrossRef]
- Shibayama, T.; Makise, N.; Motoi, T.; Mori, T.; Hiraoka, N.; Yonemori, K.; Watanabe, S.I.; Esaki, M.; Morizane, C.; Okuma, T.; et al. Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases: A Proposal of Risk Stratification and Identification of a Synaptophysin-positive Aggressive Subset. Am. J. Surg. Pathol. 2021, 45, 616–626. [Google Scholar] [CrossRef]
- Shiba, S.; Imaoka, H.; Shioji, K.; Suzuki, E.; Horiguchi, S.; Terashima, T.; Kojima, Y.; Okuno, T.; Sukawa, Y.; Tsuji, K.; et al. Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: A multicenter retrospective study. BMC Cancer 2018, 18, 993. [Google Scholar] [CrossRef]
- Wu, X.; Li, B.; Zheng, C.; Hong, T.; He, X. Clinical characteristics of epithelioid hemangioendothelioma: A single-center retrospective study. Eur. J. Med. Res. 2019, 24, 16. [Google Scholar] [CrossRef]
- Witte, S.; Weidema, M.; Kaal, S.; Versleijen-Jonkers, Y.; Flucke, U.; van der Graaf, W.; Desar, I. The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options. Semin. Oncol. 2021, 48, 111–118. [Google Scholar] [CrossRef]
- Liu, Z.; He, S. Epithelioid Hemangioendothelioma: Incidence, Mortality, Prognostic Factors, and Survival Analysis Using the Surveillance, Epidemiology, and End Results Database. J. Oncol. 2022, 2022, 2349991. [Google Scholar] [CrossRef]
- Angelini, A.; Mavrogenis, A.F.; Gambarotti, M.; Merlino, B.; Picci, P.; Ruggieri, P. Surgical treatment and results of 62 patients with epithelioid hemangioendothelioma of bone. J. Surg. Oncol. 2014, 109, 791–797. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Zhang, R.; Liu, Y.; Min, Q.; Zeng, Q.; Liu, J. Hepatic epithelioid hemangioendothelioma a case report and literature review. Int. J. Surg. Case Rep. 2023, 104, 107926. [Google Scholar] [CrossRef]
- Errani, C.; Sung, Y.S.; Zhang, L.; Healey, J.H.; Antonescu, C.R. Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet. 2012, 205, 12–17. [Google Scholar] [CrossRef] [Green Version]
- Ramkumar, S. Epithelioid Haemangioma of Bone: A Case Series and Comprehensive Literature Review Reappraising the Diagnostic Classification of All Epithelioid Vascular Neoplasms of Bone. Cureus 2021, 13, e15371. [Google Scholar] [CrossRef] [PubMed]
- Yurkiewicz, I.R.; Zhou, M.; Ganjoo, K.N.; Charville, G.W.; Bolleddu, S.; Lohman, M.; Bui, N. Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course. Am. J. Clin. Oncol. 2021, 44, 419–422. [Google Scholar] [CrossRef]
- Seavey, C.N.; Hallett, A.; Li, S.; Che, K.; Pobbati, A.V.; Ma, S.; Burtscher, A.; Kanai, R.; Lamar, J.M.; Rubin, B.P. Loss of CDKN2A cooperates with WWTR1(TAZ)-CAMTA1 gene fusion to promote tumor progression in epithelioid hemangioendothelioma. Clin. Cancer Res. 2023, CCR-22-2497. [Google Scholar] [CrossRef]
- Stacchiotti, S.; Tap, W.; Leonard, H.; Zaffaroni, N.; Baldi, G.G. New Molecular Insights, and the Role of Systemic Therapies and Collaboration for Treatment of Epithelioid Hemangioendothelioma (EHE). Curr. Treat. Options Oncol. 2023, 24, 667–679. [Google Scholar] [CrossRef] [PubMed]
- Naqvi, J.; Ordonez, N.G.; Luna, M.A.; Williams, M.D.; Weber, R.S.; El-Naggar, A.K. Epithelioid hemangioendothelioma of the head and neck: Role of podoplanin in the differential diagnosis. Head Neck Pathol. 2008, 2, 25–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Azevedo, A.S.; Follain, G.; Patthabhiraman, S.; Harlepp, S.; Goetz, J.G. Metastasis of circulating tumor cells: Favorable soil or suitable biomechanics, or both? Cell Adhes. Migr. 2015, 5, 345–356. [Google Scholar] [CrossRef]
Case | Sex/Age (Years) | Site of Primary Tumor (Focality) | Size (Centimeters) | Therapy | R/Met/P (Months) | Current Life Status, Follow-Up (Months) |
---|---|---|---|---|---|---|
1 | F/9 | Ear ** (uf) | <3.0 | E | R, 25 | NED, 276 |
2 | F/14 | Upper arm, soft tissue (uf) | <3.0 | E | No | NED, 35 |
3 | M/20 | Supraclavicular, soft tissue (met-L) | 2.4 | E + RT (adj) | No | NED, 38 |
4 | F/26 | Upper arm, bone (uf) | NA | E | No | NED, 62 |
5 | M/34 | Upper leg, soft tissue (uf) | 6.0 | E | No | NED, 242 |
6 | F/37 | Skin of the thumb (uf) | NA | E | No | NED, 72 |
7 | F/37 | Liver (mf) | 2.5 | E | No | NED, 63 |
8 | M/40 | Upper leg, soft tissue (uf) | <5.0 | E + RT (adj) | No | NED, 324 |
9 | F/41 | Groin, soft tissue (uf) | 1.8 | E + RT (adj) | Met, 35 | NED, 35 |
10 | F/49 | Mandibula, bone (met-L) | 2.5 | E | No | NED, 88 |
11 | M/59 | Heart (uf) | 8.5 | E | No | NED, 96 |
12 | F/59 | Lymph node ** (uf) | 2.0 | E + RT (adj) | Met, 57 | NED, 148 |
13 | M/59 | Axilla, soft tissue (uf) | 4.5 | E + RT (neo-adj) | No | NED, 70 |
14 | M/59 | Groin, soft tissue (uf) | 1.1 | E | No | NED, 51 |
15 | F/63 | Parotic gland (uf) | 1.6 | E | No | NED, 29 |
16 | F/66 | Liver (mf) | NA | E | No | NED, 75 |
17 | F/67 | Upper leg, soft tissue (uf) | 11.0 | E | No | NED, 33 |
18 | M/69 | Upper arm, soft tissue (uf) | 1.5 | E | No | NED, 289 |
19 | F/69 | Liver (uf) | 3.5 | E | NA | NED, 48 |
20 | M/71 | Mediastinum (uf) | 10.0 | E | No | NED, 58 |
21 | M/19 | Lung (met-M) * | NA | S | No | AWD, 112 |
22 | F/33 | Skin of the scalp (met-M) | 2.0 | Ex | No | AWD, 13 |
23 | F/41 | Supraclavicular, soft tissue (uf) | 2.5 | E + RT (adj) | Met, 19, 44, 68 | AWD, 111 |
24 | M/54 | Lung (uf) | 2.2 | E | NA | AWD, 265 |
25 | M/63 | Lower leg, bone (uf) | 3.4 | E | R + Met, 13 | AWD, 77 |
26 | M/63 | Liver (mf) | NA | Ex | P, 10 | AWD, 18 |
27 | M/66 | Lung (met-M) | NA | E | NA | AWD, 28 |
28 | F/9 | Lung (mf) | NA | S | P, 3 | DOD, 6 |
29 | F/10 | Lung (met-M) | 11.0 | E + S | P, 4 | DOD, 6 |
30 | F/32 | Skin of the scalp (met-M) | 3.0 | E + S | NA | DOD, 11 |
31 | M/33 | Pleurae (met-L) | NA | E + S | Met, 3 | DOD, 6 |
32 | M/37 | Lung (uf) | >3.0 | RT | NA | DOD, 16 |
33 | M/39 | Supraclavicular, soft tissue (met-L) | NA | RT | P, 8 | DOD, 12 |
34 | M/39 | Lung (met-M) | 5.2 | RT | No | DOD, 1 |
35 | M/39 | Mediastinum (met-M) | 5.3 | S | P + Met, 7 | DOD, 9 |
36 | M/42 | Upper leg, soft tissue (uf) | 10.0 | E | R + Met, 17 | DOD, 20 |
37 | M/42 | Lung, liver, bone (met-M) * | NA | S | Met, 19 | DOD, 23 |
38 | M/45 | Lung (met-M) | NA | S | NA | DOD, 3 |
39 | M/49 | Mandibula, bone (met-L) | 3.1 | E + RT (adj) | R + Met, 22 | DOD, 111 |
40 | F/50 | Pleurae (met-M) | NA | S | Met, 4 | DOD, 5 |
41 | M/52 | Thorax, soft tissue (uf) | NA | E + RT (unknown) | P, 19 | DOD, 19 |
42 | F/53 | Liver (mf) | NA | S | Met, 2 | DOD, 86 |
43 | F/54 | Liver (met-L) | NA | E | NA | DOD, 14 |
44 | F/55 | Upper leg, bone (uf) | 7.5 | E | Met, 9 | DOD, 10 |
45 | F/55 | Liver and pleurae (met-M) * | NA | S | NA | DOD, 3 |
46 | M/62 | Clavicular, bone (met-L) | 2.2 | E + RT (unknown) | Met, 7 | DOD, 18 |
47 | F/67 | Lower leg, soft tissue (met-M) | >5.0 | E + S | NA | DOD, 23 |
48 | M/67 | Sternum (met-M) | >5.0 | RT | NA | DOD, 3 |
49 | M/68 | Lung (uf) | 1.4 | E | R, 13 | DOD, 50 |
50 | F/68 | Pelvis, soft tissue (met-L) | NA | E | Met, 35 | DOD, 38 |
51 | F/70 | Pleurae (met-M) | NA | S | NA | DOD, 4 |
52 | F/81 | Upper leg, soft tissue (uf) | 9.0 | NA | NA | DOD, 0 |
53 | M/82 | Mediastinum (uf) | >3 | Ex | No | DOD, 2 |
54 | F/82 | Shoulder, soft tissue (met-M) | 11.0 | RT | NA | DOD, 2 |
55 | F/56 | Mediastinum (uf) | >5.0 | E | NA | DOD, 282 |
56 | F/87 | Upper leg, soft tissue (uf) | <5.0 | RT | P, 9 | DOD, 65 |
57 | F/55 | Rib (uf) | 4.5 | E | No | DOC, 139 |
Case | Necrosis | Nuclear Grade | Mitosis/10 HPF | RT-PCR | FISH | Immunohistochemistry |
---|---|---|---|---|---|---|
1 | No | Low | 0 | - | - | CAMTA |
2 | Yes | High | 1 | Neg | - | CAMTA |
3 | No | High | 0 | WWTR1-CAMTA1 | - | - |
4 | No | Low | 0 | WWTR1-CAMTA1 | - | - |
5 | No | Low | 1 | - | CAMTA | - |
6 | No | High | 0 | - | CAMTA | - |
7 | No | Low | 1 | WWTR1-CAMTA1 | - | - |
8 | No | Low | 4 | - | Neg | CAMTA |
9 | Yes | High | 0 | - | CAMTA | - |
10 | No | High | 10 | - | CAMTA | - |
11 | No | Low | 2 | - | TFE3 | |
12 | No | Low | 1 | - | CAMTA | - |
13 | No | High | 0 | - | CAMTA | - |
14 | NA | NA | NA | WWTR1-CAMTA1 | - | - |
15 | No | High | 2 | WWTR1-CAMTA1 | - | - |
16 | No | High | 0 | - | CAMTA | - |
17 | No | Low | 3 | WWTR1-CAMTA1 | - | - |
18 | No | Low | 0 | - | CAMTA | - |
19 | No | Low | 2 | - | CAMTA | - |
20 | No | Low | 2 | WWTR1-CAMTA1 | - | - |
21 | No | High | 0 | YAP1-TFE3 | - | - |
22 | No | Low | 0 | WWTR1-CAMTA1 | - | - |
23 | No | Low | 1 | WWTR1-CAMTA1 | - | - |
24 | Yes | High | 0 | WWTR1-CAMTA1 | - | - |
25 | No | High | 8 | WWTR1-CAMTA1 | - | - |
26 | NA | NA | NA | WWTR1-CAMTA1 | - | - |
27 | No | Low | 0 | - | CAMTA | - |
28 | No | Low | 0 | WWTR1-CAMTA1 | - | - |
29 | Yes | Low | 6 | - | CAMTA | - |
30 | Yes | High | 18 | - | NI | CAMTA |
31 | Yes | High | 2 | WWTR1-CAMTA1 | - | - |
32 | No | Low | 0 | - | CAMTA | - |
33 | No | Low | 1 | - | - | CAMTA |
34 | No | High | 2 | WWTR1-CAMTA1 | - | - |
35 | No | Low | 1 | WWTR1-CAMTA1 | - | - |
36 | No | Low | 7 | - | CAMTA | - |
37 | No | Low | 1 | - | CAMTA | - |
38 | No | High | 0 | - | CAMTA | - |
39 | No | Low | 0 | WWTR1-CAMTA1 | - | - |
40 | No | Low | 0 | WWTR1-CAMTA1 | - | - |
41 | NA | NA | NA | - | - | CAMTA |
42 | No | High | 4 | - | - | CAMTA |
43 | No | Low | 2 | - | - | CAMTA |
44 | No | Low | 4 | WWTR1-CAMTA1 | NI | - |
45 | No | Low | 0 | Neg | CAMTA | - |
46 | No | High | 2 | - | CAMTA | - |
47 | Yes | Low | 3 | - | - | CAMTA |
48 | No | Low | 6 | - | CAMTA | - |
49 | Yes | High | 0 | WWTR1-CAMTA1 | - | - |
50 | NA | NA | NA | - | - | CAMTA |
51 | No | Low | 0 | WWTR1-CAMTA1 | - | - |
52 | Yes | High | 1 | WWTR1-CAMTA1 | - | - |
53 | No | High | 3 | Neg | CAMTA | - |
54 | Yes | Low | 1 | - | - | CAMTA |
55 | No | Low | 0 | - | CAMTA | - |
56 | No | Low | 0 | - | CAMTA | - |
57 | No | Low | 0 | WWTR1-CAMTA1 | - | - |
Case * | Tumor Size > 3 cm | Atypical Histology | Score |
---|---|---|---|
1 | No | No | 0 |
2 | No | Yes | 1 |
4 | - | No | - |
5 | Yes | No | 1 |
6 | - | No | - |
8 | - | No | - |
9 | No | Yes | 1 |
11 | Yes | No | 1 |
12 | No | No | 0 |
13 | Yes | No | 1 |
14 | No | - | - |
15 | Yes | No | 1 |
17 | No | Yes | 1 |
18 | Yes | No | 1 |
19 | No | No | 0 |
20 | Yes | No | 1 |
23 | No | No | 0 |
24 | No | Yes | 1 |
25 | Yes | Yes | 2 |
32 | Yes | No | 1 |
36 | Yes | No | 1 |
41 | - | - | - |
44 | Yes | No | 1 |
49 | No | Yes | 1 |
52 | Yes | Yes | 2 |
53 | Yes | Yes | 2 |
55 | Yes | No | 1 |
56 | - | No | - |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tomassen, T.; Versleijen-Jonkers, Y.M.H.; Hillebrandt-Roeffen, M.H.S.; Van Cleef, P.H.J.; van Dalen, T.; Weidema, M.E.; Desar, I.M.E.; Flucke, U.; van Gorp, J.M. Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases. Cancers 2023, 15, 3304. https://doi.org/10.3390/cancers15133304
Tomassen T, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, Van Cleef PHJ, van Dalen T, Weidema ME, Desar IME, Flucke U, van Gorp JM. Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases. Cancers. 2023; 15(13):3304. https://doi.org/10.3390/cancers15133304
Chicago/Turabian StyleTomassen, Tess, Yvonne M. H. Versleijen-Jonkers, Melissa H. S. Hillebrandt-Roeffen, Patricia H. J. Van Cleef, Thijs van Dalen, Marije E. Weidema, Ingrid M. E. Desar, Uta Flucke, and Joost M. van Gorp. 2023. "Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases" Cancers 15, no. 13: 3304. https://doi.org/10.3390/cancers15133304
APA StyleTomassen, T., Versleijen-Jonkers, Y. M. H., Hillebrandt-Roeffen, M. H. S., Van Cleef, P. H. J., van Dalen, T., Weidema, M. E., Desar, I. M. E., Flucke, U., & van Gorp, J. M. (2023). Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases. Cancers, 15(13), 3304. https://doi.org/10.3390/cancers15133304